Effect of Itraconazole or Rifampin on Zilurgisertib Pharmacokinetics When Administered Orally in Healthy Participants
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1553 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Yan-Ou Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Pharmacometrics, Incyte Corporation, Wilmington, DE, USA. Hauptthemen laut MEDLINE: Rifampin, Itraconazole, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Inducers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Zilurgisertib is an oral, activin receptor‐like kinase 2 (ALK2) inhibitor being developed for the treatment of patients with fibrodysplasia ossificans progressiva. In vitro metabolism studies suggest zilurgisertib is primarily eliminated via cytochrome P450 (CYP) 3A4/5‐mediated metabolism, with an additional contribution from renal excretion. A drug‐drug interaction study was conducted to evaluate the impact of the strong CYP3A inhibitor itraconazole and the strong CYP3A4 inducer rifampin on the pharmacokinetics of zilurgisertib in healthy participants. Participants in Cohort 1 (n = 18) received zilurgisertib 100 mg on Days 1 and 10 and itraconazole 200 mg once daily on Days 6‐13. Participants in Cohort 2 (n = 18) received zilurgisertib 100 mg on Days 1 and 13 and rifampin 600 mg once daily on Days 6‐15. With the concomitant administration of itraconazole, the geometric mean maximum plasma drug concentration (C max ) and area under the concentration‐time curve from time 0 to infinity (AUC 0‐inf ) of zilurgisertib increased by 1.28‐ and 2.13‐fold, respectively. With the concomitant administration of rifampin, there was a 2.27‐ and 4.76‐fold reduction in the geometric mean C max and AUC 0‐inf of zilurgisertib, respectively. No dose‐limiting toxicities occurred in either cohort, and all treatment‐emergent adverse events were Grade 1 in severity. Zilurgisertib dose adjustment may be necessary with concomitant administration of strong CYP3A4 inhibitors, and coadministration of zilurgisertib with strong CYP3A4 inducers is not recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Pharmacometrics, Incyte Corporation, Wilmington, DE, USA.
- Department of Bioanalysis, Incyte Corporation, Wilmington, DE, USA.
- Department of Early Development, Incyte Corporation, Wilmington, DE, USA.
Zitieren
APA
Yang, Y. O., Gong, X., Wang, P., Liu, X., Getsy, J., Sheng, J., Yeleswaram, S., Chen, X., & Rockich, K. (2025). Effect of Itraconazole or Rifampin on Zilurgisertib Pharmacokinetics When Administered Orally in Healthy Participants. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1553
Vancouver
Yang YO, Gong X, Wang P, Liu X, Getsy J, Sheng J, et al. Effect of Itraconazole or Rifampin on Zilurgisertib Pharmacokinetics When Administered Orally in Healthy Participants. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1553
BibTeX
@article{Yang2025,
author = {Yang, Yan-Ou and Gong, Xiaohua and Wang, Phillip and Liu, Xiang and Getsy, Jay and Sheng, Jennifer and Yeleswaram, Swamy and Chen, Xuejun and Rockich, Kevin},
title = {Effect of Itraconazole or Rifampin on Zilurgisertib Pharmacokinetics When Administered Orally in Healthy Participants},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1553}
}
EUVIMED